# The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation

> **NCT02013037** · PHASE3 · COMPLETED · sponsor: **Cedars-Sinai Medical Center** · enrollment: 36 (actual)

## Conditions studied

- Antibody-mediated Rejection
- Hyperacute Rejection of Cardiac Transplant
- Left Ventricular Dysfunction
- Cardiac Allograft Vasculopathy
- Heart Graft Dysfunction

## Interventions

- **DRUG:** Eculizumab

## Key facts

- **NCT ID:** NCT02013037
- **Lead sponsor:** Cedars-Sinai Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11
- **Primary completion:** 2019-12-30
- **Final completion:** 2020-04-30
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2021-05-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02013037

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02013037, "The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT02013037. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*